Evidence map›Paper›PMID 42877637›Full record

ArticleFrontiers in oncology2026

Multi-parameter optimization of a novel anti-TROP2 MMAE antibody-drug-conjugate for solid tumor therapy.

Laurence Fayadat-Dilman, Andrew B Waight, Lauren Adams, Peyman Akbari, Minilik Angagaw, Jeanne Baker, Michelle Castor, Andy Chen, Daoyang Chen, Ming-Tang Chen and 37 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

47 authors.

Laurence Fayadat-DilmanDiscovery Biologics, Merck & Co., Inc., South San Francisco, CA, United States.
Andrew B WaightDiscovery Biologics, Merck & Co., Inc., South San Francisco, CA, United States.
Lauren AdamsPharmacokinetics, Dynamics, Metabolism and Bioanalytics (PDMB), Merck & Co., Inc., South San Francisco, CA, United States.
Peyman AkbariQuantitative Bioscience, Merck & Co., Inc., South San Francisco, CA, United States.
Minilik AngagawQuantitative Bioscience, Merck & Co., Inc., Boston, MA, United States.
Jeanne BakerDiscovery Biologics, Merck & Co., Inc., South San Francisco, CA, United States.
Michelle CastorDiscovery Biologics, Merck & Co., Inc., Boston, MA, United States.
Andy ChenDiscovery Biologics, Merck & Co., Inc., South San Francisco, CA, United States.
Daoyang ChenDiscovery Biologics, Merck & Co., Inc., South San Francisco, CA, United States.
Ming-Tang ChenDiscovery Biologics, Merck & Co., Inc., Boston, MA, United States.
Ellen ChienDiscovery Biologics, Merck & Co., Inc., South San Francisco, CA, United States.
Jill E ChrencikDiscovery Chemistry, Merck & Co., Inc., South San Francisco, CA, United States.
Darcey ClarkNon-clinical Drug Safety, Merck & Co., Inc., South San Francisco, CA, United States.
James DutkoDiscovery Chemistry, Merck & Co., Inc., West Point, PA, United States.
Mehabaw DerebeDiscovery Biologics, Merck & Co., Inc., South San Francisco, CA, United States.
Alan GogginsPharmacokinetics, Dynamics, Metabolism and Bioanalytics (PDMB), Merck & Co., Inc., South San Francisco, CA, United States.
Thomas GriffithsNon-clinical Drug Safety, Merck & Co., Inc., West Point, PA, United States.
Mee Ra HeonDiscovery Chemistry, Merck & Co., Inc., West Point, PA, United States.
Marlene C HintonQuantitative Bioscience, Merck & Co., Inc., Boston, MA, United States.
SuChun HsiehPharmacokinetics, Dynamics, Metabolism and Bioanalytics (PDMB), Merck & Co., Inc., South San Francisco, CA, United States.
Amy HsuDiscovery Biologics, Merck & Co., Inc., South San Francisco, CA, United States.
Zhong L HuaDiscovery Oncology, Merck & Co., Inc., South San Francisco, CA, United States.
Mark IbrahimDiscovery Biologics, Merck & Co., Inc., Boston, MA, United States.
Mengxuan JiaPharmacokinetics, Dynamics, Metabolism and Bioanalytics (PDMB), Merck & Co., Inc., South San Francisco, CA, United States.
Rebecca E JohnsonDiscovery Chemistry, Merck & Co., Inc., South San Francisco, CA, United States.
Simon B LangDiscovery Chemistry, Merck & Co., Inc., South San Francisco, CA, United States.
Su-Yang LiuQuantitative Bioscience, Merck & Co., Inc., South San Francisco, CA, United States.
Daniel MalashockDiscovery Biologics, Merck & Co., Inc., South San Francisco, CA, United States.
Aleksandra OlowData AI and Genome Science, Merck & Co., Inc., South San Francisco, CA, United States.
Michael OropalloNon-clinical Drug Safety, Merck & Co., Inc., West Point, PA, United States.
Andrea T PartridgeDiscovery Chemistry, Merck & Co., Inc., West Point, PA, United States.
Vin PenaflorQuantitative Bioscience, Merck & Co., Inc., South San Francisco, CA, United States.
Elnaz Rasti BoroujeniDiscovery Biologics, Merck & Co., Inc., South San Francisco, CA, United States.
Zhao RenQuantitative Bioscience, Merck & Co., Inc., South San Francisco, CA, United States.
Karthik SathiyamoorthyDiscovery Biologics, Merck & Co., Inc., South San Francisco, CA, United States.
Makiko UchidaDiscovery Biologics, Merck & Co., Inc., South San Francisco, CA, United States.
Derek WiswellPharmacokinetics, Dynamics, Metabolism and Bioanalytics (PDMB), Merck & Co., Inc., South San Francisco, CA, United States.
Jane XiaDiscovery Oncology, Merck & Co., Inc., South San Francisco, CA, United States.
Peng YangQuantitative Bioscience, Merck & Co., Inc., South San Francisco, CA, United States.
Jennifer YearleyQuantitative Bioscience, Merck & Co., Inc., South San Francisco, CA, United States.
Sultan YilmazDiscovery Biologics, Merck & Co., Inc., South San Francisco, CA, United States.
Yao YuDiscovery Biologics, Merck & Co., Inc., South San Francisco, CA, United States.
John A FlygareDiscovery Chemistry, Merck & Co., Inc., South San Francisco, CA, United States.
Bernhard H GeierstangerDiscovery Biologics, Merck & Co., Inc., South San Francisco, CA, United States.
Jianzhong WenPharmacokinetics, Dynamics, Metabolism and Bioanalytics (PDMB), Merck & Co., Inc., South San Francisco, CA, United States.
W Michael SeganishDiscovery Chemistry, Merck & Co., Inc., South San Francisco, CA, United States.
Edward P BowmanDiscovery Oncology, Merck & Co., Inc., South San Francisco, CA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

TROP2 is expressed in many epithelial tumors including breast and lung cancers. It is a clinically validated ADC target based on approvals of sacituzumab govitecan for triple-negative breast cancer and datopotamab deruxtecan for HR-positive, HER2-negative breast cancer. An alternative cytotoxic approach was previously tested with PF-06664178/RN927C, an anti-TROP2 ADC with an auristatin payload, which entered clinical studies but could not be dosed efficaciously due to dose-limiting toxicities including skin rash, mucosal inflammation, and neutropenia. TroptimAb-SL-MMAE was engineered using an optimized anti-TROP2 sacituzumab antibody sequence (TroptimAb) to address issues related to hydrophobicity, non-specific uptake, and ADC developability. Sacituzumab was re

Indexed as

antibody-drug-conjugateavidity tuninghydrophobicityMMAEmonoclonal antibodysolid tumorsstable linkerTrop2

Identifiers

PMID42877637
PMCPMC13662851

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.